Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPT904 in IgE-Mediated Food Allergy
NCT07220811Phase 2Recruiting
- Sponsor
- RAPT Therapeutics
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ozureprubart in food allergy (3 arms), sponsored by RAPT Therapeutics. Primary endpoint: Ability to consume a food without dose-limiting symptoms during a DBPCFC at 24 weeks. Started Oct 2025; status: recruiting.
02
Drugs
ozureprubart
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT07220811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220811.